Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Moleculin Bio acquires new brain cancer candidate; shares ahead 4% premarket

Published 08/16/2017, 08:21 AM
Updated 08/16/2017, 08:21 AM
© Reuters.  Moleculin Bio acquires new brain cancer candidate; shares ahead 4% premarket
  • Nano cap Moleculin Biotech (NASDAQ:MBRX) perks up 4% premarket on light volume in response to its announcement that it has secured exclusive access to a "significant quantity" of GMP-quality WP1122, a drug compound that it says has the potential to be a new approach to treating brain tumors, from its sublicense partner in Poland.
  • Research at MD Anderson in animal models showed that WP1122 has the potential to outperform current standard-of-care treatment for glioblastoma.
  • The company plans to accelerate preclinical toxicology and analytical testing of the compound in preparation for an IND filing in the U.S.
  • Now read: U.S. DoD to launch pilot study of Pluristem's PLX-R18 cell therapy for radiation exposure; shares ahead 4% premarket


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.